<DOC>
	<DOCNO>NCT00803673</DOCNO>
	<brief_summary>This study look new formulation GSK573719 see safe tolerate healthy volunteer</brief_summary>
	<brief_title>A Healthy Volunteer Study With Inhaled GSK573719 Placebo</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy . Male female 18 65 year age inclusive . Nonchildbearing woman woman child bear potential agree use contraception Subject CYP2D6 genotype confirm include either follow part : Part 1 : may include extensive , intermediate ultrarapid metabolizers Part 2 : include poor ( enzyme activity ) metabolizers , previously confirm phenotype Body Mass Index within range 18 30 kg/m2 ( inclusive ) . Capable give write informed consent Normal ECG ; Normal lung function . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) A sign date write informed consent obtain subject The subject capable give informed consent Available complete study Any clinically important abnormality identify screen medical assessment ( physical examination/medical history ) , clinical laboratory test , ECG ( 12lead ) . 24hr Holter monitoring outside normal limit . A history breathing problem ( i.e . history asthmatic symptomatology ) . Abnormal ECG . Abnormal blood pressure . Abnormal heart rate The subject positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within three month screen . A positive test HIV antibody ( determined local SOPs ) . History high alcohol consumption within three month study The subject participate clinical trial receive IP within follow time period prior first dose day current study : 30 day , five halflives twice duration biological effect IP ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , ( except simple analgesic e.g . paracetamol ) , include vitamin , herbal dietary supplement ( include St John 's Wort ) within seven day ( 14 day drug potential enzyme inducer ) five halflives ( whichever longer ) prior first dose study medication History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500mL within 56 day period . Unwillingness inability follow procedure outline protocol . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product prior screen . The subject unable use novel dry powder inhaler correctly . The subject know allergy hypersensitivity milk protein excipients magnesium stearate lactose monohydrate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>New formulation</keyword>
</DOC>